DexCom is a company that makes special devices to help people with diabetes keep track of their blood sugar levels. Some people who work at big financial companies have been buying and selling special contracts called options on DexCom's stock. This article is about what those options are and what it might mean for the stock price. Read from source...

- The article is poorly written, with many grammatical and spelling errors.
- The article does not provide any clear evidence or data to support its claims about DexCom's unusual options activity.
- The article relies on anonymous sources and vague references to "analysts" and "market movers" without providing any specific names or details.
- The article uses misleading and exaggerated language, such as "conspicuous bullish move" and "major market movers", without providing any actual numbers or percentages to back up these claims.
- The article seems to have a negative bias against DexCom, as it focuses on the "unusual" and "bearish" trades, while ignoring the overall positive sentiment and higher volume of bullish trades.
- The article fails to mention any potential reasons or motivations behind the options activity, such as upcoming earnings, clinical trials, regulatory approvals, or competitive threats.
- The article does not provide any useful information or insights for investors, as it does not offer any recommendations, strategies, or trade ideas based on the options data.
- The article is overly sensationalized and fear-mongering, as it tries to scare readers with phrases like "predicted price range" and "trading volume stands at", without explaining how these numbers are derived or what they mean for the stock.
- The article is outdated and irrelevant, as it focuses on options activity from three months ago, while the stock has moved significantly since then.

The sentiment for this article is bullish.

Given the unusual options activity for DexCom on July 15, I would suggest the following investment recommendations:

1. For bullish investors, consider buying a call spread strategy, with a short call at $115 and a long call at $130. This strategy will allow you to benefit from a rise in the stock price while limiting your risk. The potential profit is capped at $450 per contract, and the risk is limited to the premium paid for the long call.

2. For bearish investors, consider buying a put spread strategy, with a short put at $105 and a long put at $90. This strategy will allow you to benefit from a decline in the stock price while limiting your risk. The potential profit is capped at $450 per contract, and the risk is limited to the premium paid for the long put.

3. For neutral investors, consider selling a straddle strategy, with a short call at $115 and a short put at $105. This strategy will allow you to collect a premium while being exposed to both a rise and a fall in the stock price. The potential risk is unlimited, and the potential profit is limited to the premium received for the straddle.

As for the risks, the main risk factors to consider are the upcoming earnings announcement, the potential impact of the COVID-19 pandemic on the company's operations and demand for its products, and the competitive landscape in the continuous glucose monitoring industry. Additionally, options trading involves significant risks, and investors should be prepared to manage their positions and adjust their strategies as market conditions change.